Comparing Results for 3-Drug and 2-Drug Regimens in Relapsed/Refractory Myeloma
Paul G. Richardson, MD, clinical program leader and director of Clinical Research in the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses results from the phase III OPTIMISMM trial comparing treatment regimens for relapsed/refractory multiple myeloma. This data compares a regimen of pomalidomide, bortezomib, and dexamethasone versus bortezomib and dexamethasone alone.
Paul G. Richardson, MD, clinical program leader and director of Clinical Research in the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses results from the phase III OPTIMISMM trial comparing treatment regimens for relapsed/refractory multiple myeloma. This data compares a regimen of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone versus bortezomib and dexamethasone alone.
The results for the 3-drug regimen over the 2-drug regimen were quite striking, Richardson says. The first thing they noted as significant was the progression-free survival. For patients who had progressed or relapsed after 1 prior line of therapy, there was significant clinical benefit over 10 months.
The hazard ratio in the experimental arm was 0.5, which Richardson says was also very meaningful. The response rate overall was 82% in the experimental arm versus around 60% in the control arm.
Fellow's Perspective: Impact of Quadruplet and MRD in Newly Diagnosed Multiple Myeloma
December 17th 2024In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about how recent trials shape their approach for a patient with transplant-eligible multiple myeloma.
Read More
